



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

International Patent Application of

GOLDSPINK et al.

Serial No. 09/852,261

Filed: May 10, 2001

For: REPAIR OF NERVE DAMAGE

Atty. Ref.: 117-351

Group:

Examiner:

* * * * *

June 5, 2001

Assistant Commissioner for Patents
Washington, DC 20231

SUBMISSION OF PRIORITY DOCUMENTS

Sir:

It is respectfully requested that this application be given the benefit of the foreign filing date under the provisions of 35 U.S.C. §119 of the following, a certified copy of which is submitted herewith:

Application No.

0011278.9

Country of Origin

GREAT BRITAIN

Filed

10 May 2000

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 

B. J. Sadoff

Reg. No. 36,663

BJS:eaw
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100





INVESTOR IN PEOPLE




The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andrew*

Dated 21 May 2001





The
**Patent
Office**

11MAY00 E535911-4 D00192

P01/7700 0.00-0011278.9

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form))

The Patent Office

Cardiff Road
Newport
Gwent NP10 8QQ

1. Your reference

P.77091A TAC

2. Patent application number

(The Patent Office will fill in this part)

0011278.9

110 MAY 2000

3. Full name, address and postcode of the or of each applicant (underline all surnames)

UNIVERSITY COLLEGE LONDON
Gower Street
London WC1E 9BT
United Kingdom

Patents ADP number (if you know it)

798652002

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

REPAIR OF NERVE DAMAGE

5. Name of your agent (if you have one)

J A KEMP & CO

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

14 SOUTH SQUARE
GRAY'S INN
LONDON WC1R 5LX

Patents ADP number (if you know it)

26001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer "Yes" if:

NO

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body:
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	47
Claim(s)	3
Abstract	1
Drawing(s)	11

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents


Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application

Signature  Date 10 May 2000

12. Name and daytime telephone number of person to contact in the United Kingdom T.A. CRESSWELL
020 7405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue of a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered "Yes" Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

REPAIR OF NERVE DAMAGE

FIELD OF THE INVENTION

5 The present invention concerns the treatment of nerve damage with the Insulin-like Growth Factor I (IGF-I) isoform known as mechano growth factor (MGF). More particularly, MGF is localised around the sites of such damage to effect repair, typically by means of the placement of a conduit around the two ends of a severed peripheral nerve.

10

BACKGROUND OF THE INVENTION

IGF-I and MGF

15 Mammalian IGF-I polypeptides have a number of isoforms, which arise as a result of alternative mRNA splicing. Broadly, there are two types of isoform, liver-type isoforms and non-liver ones. Liver-type isoforms may be expressed in the liver or elsewhere but, if expressed elsewhere, are equivalent to those expressed in the liver. They have a systemic action and are the main isoforms in mammals. Non-liver
20 isoforms are less common and some are believed to have an autocrine/paracrine action. A cDNA of the latter type has been cloned, as discussed below, following detection in skeletal and cardiac muscle undergoing mechanical overload.

The terminology for the IGF-I splice variants is based on the liver isoforms (Chew *et al*, 1995) and has not fully evolved to take into account those produced by non-liver
25 tissues. The latter are controlled to some extent by a different promoter (promoter 1) to the liver IGF-I isoforms, which respond to hormones and are under the control of promoter 2 (Layall, 1996).

30 For the purposes of this invention, two isoforms are of particular interest. These are both expressed in skeletal muscle, though it has only recently been appreciated that

two muscle isoforms exist. The first isoform is muscle liver-type IGF-I or L.IGF-I (systemic type), which is of interest mainly for comparative purposes. The second is mechano-growth factor or MGF (autocrine/paracrine type).

5 These are alternative splice variants. Exons 1 and 2 are alternative leader exons (Tobin *et al*, 1990; Jansen *et al*, 1991) with distinct transcription start sites which are differentially spliced to common exon 3. Exons 3 and 4 code for the mature IGF-I peptide (B, C, A and D domains) as well as the first 16 amino acid of the E domain. Exons 5 and 6 each encodes an alternative part of a distinct extension peptide, the E
10 domain. This is followed by the termination codons of precursor IGF-I, 3' untranslated regions and poly(A) addition signal sites (Rotwein *et al*, 1986). A further difference between the two isoforms is that MGF is not glycosylated and is therefore smaller. It has also been shown to be less stable. It may thus have a shorter half-life.

15 It has been shown that MGF, which is not detectable in skeletal muscle unless it is subjected to exercise or stretch (Yang *et al*, 1996), has exons 4, 5 and 6 whilst the muscle L.IGF-I has exons 4 and 6. Exon 5 in MGF has an insert of 52 bp which changes the 3' reading frame and hence the carboxy end of the peptide. In addition,
20 MGF has been detected in overloaded cardiac muscle (Skarli *et al*, 1998).

Functional epitope mapping of IGF-I using a battery of monoclonal antibodies (Mañes *et al*, 1997) has shown that the carboxy terminus (3' end) of IGF-I is important in determining the affinity of the peptide for a particular receptor and/or
25 binding protein.

MGF mRNA is not detected in dystrophic muscle even when it is subjected to stretch. The inability of muscle in both the autosomal- and dystrophin-deficient dystrophies to respond to overload by stretch (Goldspink *et al*, 1996) indicates that
30 the cytoskeleton may be involved in the transduction mechanism. It is probable that there is a basic mechanism that detects muscle overload and which results in the

expression of both variant forms of IGF.

Thus, MGF is known to be expressed in skeletal and cardiac muscle tissue in response to stretch and exercise and as a result is believed to be involved in repair of damage to muscle (Yang *et al*, 1996; WO97/33997). This has been confirmed more recently by McKoy *et al* (1999).

Conduits

It has previously been proposed to use a conduit to assist in nerve damage repair, e.g. to bridge a gap in a severed nerve. The aim is to place the conduit around the nerve, e.g. around its two severed ends, so that the nerve will regrow within the conduit.

In particular, conduits composed of Poly-3-hydroxy-butyrate have been proposed as an alternative to nerve autografts, which result in sub-optimal functional results and donor site morbidity. PHB occurs within bacterial cytoplasm as granules and is available as bioabsorbable sheets. PHB conduits have been shown to assist in nerve regeneration and to show good results compared to nerve autografts (Hazari *et al*, J. Plastic Surgery (1999)).

Various different conduit materials have been proposed, including PHB, but none have yet been fully applied clinically. Only silicone has been applied, in a restricted clinical trial (Lundborg *et al*, 1997), but a second operation has sometimes been necessary to remove the non-resorbable silicone tube.

SUMMARY OF THE INVENTION

We have now identified a new and surprising property of MGF.

Plasmids containing MGF DNA operably linked to expression signals capable of securing expression in muscles were prepared and injected intramuscularly into rats.

Expression of MGF *in vivo* resulted. To investigate the effect of MGF on the animal's nerves, the right-facial nerve was damaged by avulsion in some animals and crushing in others. Similar experiments were performed with plasmids capable of expressing L.IGF-I and control experiments were also carried out using equivalent
5 "empty" plasmids lacking an MGF or L.IGF-I coding sequence, and with non-operated rats.

The surgical procedures carried out normally result in massive motoneurone loss, and that was the case in the control animals. However, in the case of nerve avulsion, use
10 of L.IGF-I reduced motoneurone loss to about 50% and use of MGF reduced motoneurone loss to about 20%. Although both isoforms were found to be effective in promoting motoneurone rescue, MGF was, surprisingly, more than twice as effective as L.IGF-I. This opens up the possibility of using MGF in the treatment of neurological disorders, especially motoneurone disorders. Additionally, it should be
15 noted that this is the first time that altered availability of neurotrophic factors to intact adult motoneurons has been shown to affect a subsequent response to injury and also that this is the first time that intramuscular gene transfer using plasmid DNA has been shown to be an effective strategy for motoneuronal rescue.

20 IGF-I isoforms have specific binding proteins which determine their action, particularly in terms of which tissues the isoform takes effect in. It appears that the binding protein for MGF is located in the central nervous system (CNS) as well as in skeletal and cardiac muscle. This may explain its greater effectiveness. Also, the fact that MGF is not glycosylated and thus smaller than L.IGF-I may facilitate its
25 transfer from the muscle to the motor neuron cell bodies in the CNS.

These findings have general applicability to the treatment of neurological disorders and are surprising because MGF had previously only been detected in cardiac muscle and skeletal muscle under stretch/exercise. Chew (1995) suggests that an IGF-I Ec
30 form is found in the liver. However, this is detectable in very low amounts and may be due to leaky transcription. Therefore, it had previously been believed that MGF

was a muscle-specific isoform whereas it has now emerged that it is also implicated in repairing damage to the nervous system and can thus form the basis of treatments for disorders of the nervous system.

5 Moreover, these findings lead us to believe that MGF will be useful in repairing nerve damage, especially in the peripheral nervous system (PNS), when localised around the site of the damage. In particular, MGF will be useful in repairing nerve damage in conjunction with a conduit placed around the two ends of a severed nerve. The properties of MGF in nerve regeneration, as identified by the present Inventors,
10 can be combined with the tendency of such conduits to facilitate nerve regeneration. This will result in an improved conduit-based means of repairing nerve damage. Other means of localising MGF at the site of damage can also be used.

Accordingly, the invention provides:

15 Use of an MGF (mechano-growth factor) Insulin-like Growth Factor I (IGF-I) isoform comprising amino acid sequences encoded by nucleic acid sequences of IGF-I exons 4, 5 and 6 in the reading frame of MGF and having the ability to reduce motoneurone loss by 20% or greater in response to nerve avulsion, in the
20 manufacture of a medicament for the treatment of nerve damage by localisation of MGF at the site of the damage.

The invention also provides:

25 A product comprising:

- (a) an MGF IGF-I isoform of the invention; and
- (b) a conduit of the invention; and optionally
- (c) a polypeptide growth factor which prevents or diminishes
30 degeneration; and optionally

- (d) another neurologically active agent

for simultaneous, separate or sequential use in the treatment of nerve damage.

5

The invention also provides:

A kit for the treatment of nerve damage comprising:

- 10 (a) an MGF IGF-I isoform of the invention; and
 (b) a conduit of the invention; and optionally
 (c) a polypeptide growth factor which prevents or diminishes
 degeneration; and optionally
 (d) another neurologically active agent.

15

The invention also provides:

A method of treating nerve damage comprising administering to a
subject in need thereof an effective non-toxic amount of an MGF IGF-I isoform as
20 defined in any one of claims 1, 9, 10 or 11 by localising said MGF at the site of said
damage.

BRIEF DESCRIPTION OF THE DRAWINGS

25 **FIGURE 1:** Total numbers of motoneurones in the facial motor nucleus

KEY

- | | | | |
|-------|------------------|----|----------------------------------|
| 1: | normal | 4: | plasmid only - 1 month avulsion |
| 2: | 1 month crush | 5: | IGF-I plasmid - 1 month avulsion |
| 30 3: | 1 month avulsion | 6: | MGF plasmid - 1 month avulsion |

right: operated side; left: non-operated side

FIGURE 2: Avulsion (control experiments)

(a) Low magnification view of a transverse section through the brainstem at the level of the facial nucleus, 1 month following facial nerve avulsion. Numbers of motoneurons in the facial nucleus of the operated side (b) are markedly reduced compared to the non-operated nucleus (arrow and inset c). 70 μ m vibratome section stained with YOYO and viewed using epifluorescence.

FIGURE 3: Plasmid experiments

(a) Low magnification view of the brainstem at the level of the facial nucleus. Plasmid DNA without any gene insert was injected into the right snout muscle. 7 days later the right facial nerve was avulsed and the animal allowed to survive for 1 month. Like the effect of avulsion only (Figure 1), numbers of motoneurons in the facial nucleus of the operated side (c) are markedly reduced compared to the non-operated nucleus (arrow and inset b). 70 μ m vibratome section stained with YOYO and viewed using epifluorescence.

FIGURE 4: MGF plasmid experiments

(a) Low magnification view of the brainstem at the level of the facial nucleus. Plasmid DNA containing the rat MGF gene was injected into the right snout muscle. 7 days later the right facial nerve was avulsed and the animal allowed to survive for 1 month. Numbers of motoneurons in the facial nucleus of the operated side (b) are similar to the non-operated nucleus (arrow and inset c). 70 μ m vibratome section stained with YOYO and viewed using epifluorescence.

FIGURE 5: cDNA and amino acid sequence of human MGF, showing its exon structure

FIGURE 6: cDNA and amino acid sequence of rat MGF, showing its exon

structure

5

FIGURE 7: cDNA and amino acid sequence of rabbit MGF, showing its exon structure

FIGURE 8: cDNA and amino acid sequence of human L-IGF-I, showing its exon structure

10

FIGURE 9: cDNA and amino acid sequence of rat L-IGF-I, showing its exon structure

FIGURE 10: cDNA and amino acid sequence of rabbit L-IGF-I, showing its exon structure

15

FIGURE 11: Sequence alignment, illustrating exon structure of human, rat and rabbit MGF and L-IGF-I, and highlighting similarities and differences.

DETAILED DESCRIPTION OF THE INVENTION

20

The present invention concerns the use of MGF in the treatment of neurological disorders, preferably motoneurone disorders.

MGF polypeptides and polynucleotides

Polypeptides

25

30

MGF stands for mechano-growth factor (cf. McKoy *et al*, 1999). As discussed above and explained in more detail in Chew *et al* (1995), Yang *et al* (1996) and McKoy *et al* (1999), MGF is an alternatively spliced variant of IGF-I. Liver-type IGF-I comprises amino acids encoded by exons 4 and 6 whereas MGF comprises amino acids encoded by exons 4, 5 and 6. MGF also has an altered reading frame at its carboxy terminus as a result of a 52 bp insert in exon 5, and is smaller because it is

not glycosylated. Chew *et al* (1995) and Yang *et al* (1996) did not use the term MGF, but rather IGF-I Ec, to define the 4-5-6 splice variant. The muscle isoform that has the Ec domain is now known as MGF (cf McKoy *et al*, 1999). It is now clear that the particular form of the IGF-I Ec is produced by cardiac and skeletal muscle but only when they are subjected to mechanical activity.

Herein, MGF is understood to mean any IGF-I polypeptide having the 4-5-6 exon structure and the neurological properties identified by the Inventors, as discussed further below. The exon structure of MGF in human, rat and rabbit is illustrated in Figures 5, 6 and 7 (SEQ ID NOs. 1/2, 3/4 and 5/6). For comparison, the exon structure of human, rat and rabbit L.IGF-I is given in Figures 8, 9 and 10 (SEQ ID NOs. 9/10, 11/12 and 13/14), and a comparison between MGF and L-IGF-I is made in Figure 11.

Preferably, MGF of the invention will have the reading frame which, in native MGF, is generated by the 52 bp insert mentioned above. Preferably, MGF of the invention will not be glycosylated. However, it may be glycosylated or partially glycosylated in some embodiments. By partially glycosylated is meant up to 10, 20, 30, 50, 70, 80, 90, 95 or 99% as much glycosylation as L.IGF-I, e.g. containing some, but not all, of IGF-I's glycosylation sites. The pattern of glycosylation may be the same as that of L.IGF-I in terms of the type and placement of sugars or it may be different.

Preferably, MGFs of the invention comprise exons 3, 4, 5 and 6 on equivalent sequences. Optionally, they may include exons 1 and/or 2, or equivalent sequences as well.

MGF of the invention may find its origins in any species that has 4-5-6 spliced IGF-I. Thus, MGF of the invention may have the sequence of human MGF, which is generally preferred. MGF having the sequence of an animal MGF may also be used, e.g. rat, rabbit, mouse, cow, sheep, goat, chicken, dog, cat MGF. Preferably, the species origin of the MGF used will be matched to the species of the subject to be

treated. In particular, it is preferred to use human MGF to treat human patients.

5 The sequences of exons 3, 4, 5 and 6 human MGF (IGF-I-Ec) (SEQ ID NO. 1/2, Figure 5), rat MGF (SEQ ID NO. 3/4, Figure 6) and rabbit MGF (IGF-I Eb) (SEQ ID NO. 5/6, Figure 7) are given below, together with their corresponding cDNA sequences. SEQ ID NOs. 1, 3 and 5 are the cDNAs; SEQ ID NOs. 2, 4 and 6 are the polypeptides. For comparison, the sequences of exons 3, 4 and 6 human (SEQ ID NO. 9/10, Figure 8), rat (SEQ ID NO. 11/12, Figure 9) and rabbit (SEQ ID NO. 13/14, Figure 10) liver-type IGF-I (L.IGF-I) are also given (see Figure 11 in particular for comparison). Polypeptides having the sequences of SEQ ID NOs. 2, 4 and 6 may be used in preferred embodiments of the invention.

15 Herein, MGF and functional equivalents thereof have the neurological properties identified by the Inventors. Thus, they have the capacity to effect motoneurone rescue. The exact degree of motoneurone rescue will vary from case to case, depending on which MGF is used and under what circumstances. However, with reference to the Examples, MGFs of the invention may be able to reduce motoneurone loss following nerve avulsion by up to 20, 30, 40, 50, 60, 70, 80, 90, 95, 99 or 100% in a treated subject compared to an equivalent situation in a non-
20 treated subject. Reduction of motoneurone loss by 70% or more, or 80% more (i.e. to 30% or less or 20% or less) is preferred. The degree of rescue may be calculated using any suitable technique, e.g. a known technique such as Stereology (see the Examples). As a specific test, the techniques used in the Examples, which rely on measuring motoneurone rescue in response to facial nerve avulsion in rats, may be
25 used. However it will be appreciated that this technique may not be ideal for assessing the properties of non-rat MGFs. Similar tests may thus be devised using other animal models. For example, tests relating to avulsion of other nerves may be devised. So far as human treatments are concerned, it will generally be necessary to rely on animal models so human MGF may have lower activity in these models than
30 it has *in vivo* in humans.

MGFs having the sequence of naturally occurring MGFs are preferred. However, variant MGFs having the same basic 4-5-6 exon structure and neurological properties discussed herein may also be used.

5 Polypeptides of the invention may be encoded by polynucleotides as described below.

10 An MGF polypeptide of the invention may consist essentially of the amino acid sequence set out in SEQ ID NO. 2, 4 or 6 or a substantially homologous sequence, or of a fragment of either of these sequences, as long as the neurological properties of the invention are maintained. In general, the naturally occurring amino acid sequences shown in SEQ ID NOs. 2, 4 and 6 are preferred. However, the polypeptides of the invention include homologues of the natural sequences, and fragments of the natural sequences and of their homologues, which have the
15 neurological properties of the invention.

In particular, a polypeptide of the invention may comprise:

- 20 (a) the polypeptide sequence of SEQ ID NO. 2 (human MGF), 4 (rat MGF), or 6 (rabbit MGF);
- (b) a polypeptide sequence at least 70, 80, 90, 95, 98 or 99% homologous to, a polypeptide of (a);
- (c) a sequence comprising the amino acids encoded wholly or partly by exons 4, 5 and 6 of human, rat or rabbit MGF DNA of SEQ ID NO. 1, 3, or 5, or a sequence having 70% or greater homology thereto;
25
- (d) a sequence encoded by a nucleic acid sequence capable of selectively hybridising to a sequence of (a), (b) or (c); or
- (e) an allelic variant or species homologue of a sequence of (a).

Allelic Variants

5 An allelic variant will be a variant which occurs naturally and which will function in a substantially similar manner to the protein of SEQ ID NO. 2, 4 or 6 as defined above. Similarly, a species homologue of the protein will be the equivalent protein which occurs naturally in another species. Such a homologue may occur in any species, preferably a mammalian species, for example a bovine, equine, ovine, feline or canine species; such as cow, horse, sheep or goat, cat, or dog; or in a rodent
10 species other than rat (SEQ ID NO. 4) or rabbit (SEQ ID NO. 6), or in a primate species other than human (SEQ ID NO. 2). Non-mammalian MGFs, for example piscine or avian MGFs, e.g. chicken MGF, are also MGFs of the invention. Within any one species, a homologue may exist as several allelic variants, and these will all be considered homologues of the protein of SEQ ID NO. 2, 4 or 6.

15 Allelic variants and species homologues can be obtained by methods known in the art, e.g. by probing suitable cell source with a probe derived from SEQ ID NO. 1, 3 or 5. Clones obtained can be manipulated by conventional techniques to generate a polypeptide of the invention which can be produced by recombinant or synthetic
20 techniques known *per se*.

Homologues

25 A polypeptide of the invention is preferably at least 70% homologous to the protein of SEQ ID NO. 2, 4 or 6 more preferably at least 80 or 90% and more preferably still at least 95, 97 or 99% homologous thereto over a region of at least 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous amino acids. Methods of measuring protein homology are well known in the art and it will be understood by those of skill in the art that in the present context, homology is calculated on the
30 basis of amino acid identity (sometimes referred to as "hard homology").

Degrees of homology can be measured by well-known methods, as discussed herein for polynucleotide sequences.

5 The sequence of the polypeptides of SEQ ID NOs. 2, 4 and 6 and of the allelic variants and species homologues can be modified to provide further polypeptides of the invention.

Substitutions

10 Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions. For example, a total of up to 1, 2, 5, 10 or 20 amino acids may be substituted over a length of 50, 100 or 200 amino acids in the polypeptides. For example, up to 20 amino acids substituted over any length of 50 amino acids. The modified polypeptide generally retains the neurological properties of the invention,
15 as defined herein. Conservative substitutions may be made, for example according to the following table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other.

ALIPHATIC	Non-polar	G A P
		I L V
	Polar-uncharged	C S T M
		N Q
	Polar-charged	D E
		K R
20 AROMATIC		H F W Y

Fragments

25 Polypeptides of the invention also include fragments of the above-mentioned full length polypeptides and variants thereof, including fragments of the sequence set out

in SEQ ID NOs. 2, 4 and 6. Such fragments typically retain the neurological properties of the invention.

5 Suitable fragments will generally be at least about 20, e.g. at least 20, 50 or 100 amino acids in size. Polypeptide fragments of the polypeptides of SEQ ID NOs. 2, 4 and 6 and allelic and species variants thereof may contain one or more (e.g. 2, 3, 5, 5 to 10 or more) substitutions, deletions or insertions, including conservative substitutions. Each substitution, insertion or deletion may be of any length, e.g. 1, 2, 3, 4, 5, 5 to 10 or 10 to 20 amino acids in length.

10

In particular, fragments of the invention may comprise the amino acids encoded by exons 4, 5 and 6 of human, rat or rabbit DNA of SEQ ID NO. 1, 3 or 5. The first amino acid of exon 4, Asn, is partly encoded by exon 3 (1 nucleotide) and partly by exon 4 (2 nucleotides). It is preferred that said first amino acid be present, in a
15 fragment of the invention.

15

Chimeric sequences

MGF polypeptides encoded by chimeric polypeptide sequences of the invention (see
20 below) may be used.

20

Isolation, purification and modification

Polypeptides of the invention may be in a substantially isolated form. It will be
25 understood that the polypeptide may be mixed with carriers or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated. A polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the polypeptide in a preparation in which more than 70%, e.g. more than 80, 90, 95, 98 or 99% of the
30 polypeptide in the preparation is a polypeptide of the invention.

30

Polypeptides of the invention may be provided in a form such that they are outside their natural cellular environment. Thus, they may be substantially isolated or purified, as discussed above, or in a cell which they do not occur in nature, e.g. a cell or other plant species, animals, yeast or bacteria.

5

Polypeptides of the invention may be modified for example by the addition of Histidine residues or a T7 tag to assist their identification or purification or by the addition of a signal sequence to promote their secretion from a cell.

10

A polypeptide of the invention may be labelled with a revealing label. The revealing label may be any suitable label which allows the polypeptide to be detected. Suitable labels include radioisotopes, e.g. ^{125}I , ^{35}S , enzymes, antibodies, polynucleotides and linkers such as biotin.

15

Polypeptides of the invention may be chemically modified, e.g. post-translationally modified. For example, they may comprise modified amino acid residues. They may also be glycosylated (see above), though MGF is not naturally glycosylated. Such modified polypeptides will be understood to be polypeptides of the invention.

20

Another possibility is to increase the stability, and hence half life of MGF *in vivo* by altering its sequence, e.g. to make it more amenable to glycosylation by introducing one or more glycosylation sites. Alternatively, modifications can be made that make MGF's primary amino acid structure more resistant to degradation.

25

The effects of modifications to MGF's sequence can be tested by any suitable method. For example, the binding properties and/or stability of variant MGFs can be tested by comparing them *in vitro* or *in vivo* to those of unmodified MGF.

Polynucleotides

30

Polynucleotides of the invention encode polypeptides of the invention.

Preferred polynucleotides of the invention comprise a coding sequence encoding a polypeptide having the neurological properties of the invention, which coding sequence is selected from:

- 5 (a) the coding sequence of any one of SEQ ID NO. 1, 3 or 5;
- (b) a sequence capable of selectively hybridising to a sequence of (a), or to a sequence complementary to a sequence of (a);
- (c) a sequence having 70% or more homology to a sequence of (a);
- (d) a sequence which is a fragment of the sequence of any one of (a) to
- 10 (c); and
- (e) a sequence which differs from that of any one of (a) to (d) but which, owing to the degeneracy of the genetic code, encodes the same polypeptide.

15 Thus, the invention provides polynucleotides comprising the coding sequence as shown in any one of SEQ ID NO. 1, 3 or 5 and variants thereof with related sequences. Polynucleotides of the invention can be used to prepare vectors of the invention.

20 *SEQ ID NOs. 1, 3 and 5*

Preferred polynucleotides of the invention comprise coding sequences as shown in SEQ ID NOs. 1, 3 and 5.

25 *Hybridisable sequences*

A polynucleotide of the invention may hybridise selectively to coding sequence of SEQ ID NO. 1, 3 or 5 at a level significantly above background. Background hybridisation may occur, for example because of other cDNAs present in a cDNA

30 library. The signal level generated by the interaction between a polynucleotide of the invention and the coding sequence of SEQ ID NO. 1, 3, 5, 7, 9 or 11 is typically at

least 10 fold, preferably at least 100 fold, as intense as interactions between other polynucleotides and the coding sequence of SEQ ID NO. 1, 3 or 5. The intensity of interaction may be measured, for example by radiolabelling the probe, e.g. with ^{32}P . Selective hybridisation is typically achieved using conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C, for example 45 to 50, 50 to 55 or 55 to 60°C, e.g. at 50 or 60°C.

However, such hybridisation may be carried out under any suitable conditions known in the art (see Sambrook *et al*, 1989, *Molecular Cloning: A Laboratory Manual*). For example, if high stringency is required, suitable conditions include 0.2 x SSX at around 60°C, for example 40 to 50°C, 50 to 60°C or 60 to 70°C, e.g. at 50 or 60°C. If lower stringency is required, suitable conditions include 2 x SSC at around 60°C, for example 40 to 50°C, 50 to 60°C or 60 to 70°C, e.g. at 50 or 60°C.

Stringency typically occurs in a range from about $T_m - 5^\circ\text{C}$ (5°C below the melting temperature (T_m) of the two sequences hybridising to each other in a duplex) to about 20°C to 25°C below T_m . Thus, according to the invention, a hybridisable sequence may be one which hybridises to SEQ ID NO. 1, 3 or 5 at a temperature of from T_m to $T_m - 25^\circ\text{C}$, e.g. T_m to $T_m - 5^\circ\text{C}$, $T_m - 5$ to $T_m - 10^\circ\text{C}$, $T_m - 10$ to $T_m - 20^\circ\text{C}$ or $T_m - 20$ to $T_m - 25^\circ\text{C}$.

Homologous sequences

A polynucleotide sequence of the invention, will comprise a coding sequence at least 70% preferably at least 80 or 90% and more preferably at least 95, 98 or 99%, homologous to the coding sequence of SEQ ID NO. 1, 3 or 5.

Such homology will preferably apply over a region of at least 20, preferably at least 50, for instance 100 to 500 or more, contiguous nucleotides.

Methods of measuring nucleic acid and polypeptides homology are well known in the art. These methods can be applied to measurement of homology for both polypeptides and nucleic acids of the invention. For example, the UWGCG Package provides the BESTFIT program which can be used to calculate homology (Devereux
5 *et al*, 1984, *Nucleic Acids Research* 12, p.387-395).

Similarly, the PILEUP and BLAST algorithms can be used to line up sequences (for example as described in Altschul, S.F., 1993, *J. Mol. Evol.* 30:290-300; Altschul, S.F. *et al*, 1990) *J. Mol. Biol.* 215:403-410).

10

Many different settings are possible for such programs. According to the invention, the default settings may be used.

In more detail, the BLAST algorithm is suitable for determining sequence similarity
15 and it is described in Altschul *et al* (1990) *J. Mol. Biol.* 215:403-410. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued
20 threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul *et al*, *supra*). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions
25 for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The
30 BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) *Proc. Natl. Acad. Sci. USA* 89:10915-

10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

5 The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g. Karlin and Altschul (1993) *Proc. Natl. Sci. USA* 90:5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a fused gene or cDNA if the smallest
10 sum probability in comparison of the test nucleic acid to a fused nucleic acid is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

Fragments

15

Also included within the scope of the invention are sequences which are fragments of the sequences of (a) to (c) above but have the neurological properties of the invention.

20 In particular, fragments may comprise exons 4, 5 and 6 of human, rat or rabbit MGF DNA of SEQ ID NO. 1, 3 or 5.

The first amino acid of exon 4, Asn, is partly encoded by exon 3 and partly by exon 4. It is preferred that the necessary coding bases from exon 3 are present to encode
25 said first amino acid, Asn.

Degenerate sequences

30

Also included within the scope of the invention are sequences that differ from those

of (a) to (d) but which, because of the degeneracy of the genetic code, encode the same protective polypeptides. For example, the invention provides degenerate variants of the sequence of SEQ ID NOs. 1, 3 and 5 that also encode the polypeptide of SEQ ID NOs. 2, 4 and 6.

5

Complementary sequences

In addition, the invention provides polynucleotides having sequences complementary to any of the above-mentioned sequences.

10

Chimeric sequences

Chimeric sequences comprising exons from more than one species may also be used. For example, one or more of exons 3 to 6 may be derived from human and one or more from rat and/or rabbit.

15

Further properties

The nucleic sequences of the invention may be of any length as long as they encode a polypeptide of the invention. A nucleic acid sequence according to the invention may be a contiguous fragment of the sequence of SEQ ID NO. 1, 3 or 5 or a sequence that is related to it in any of the ways described above. Alternatively, nucleic acids of the invention may comprise DNA sequences that are not contiguous in the sequence of SEQ ID NO. 1, 3 or 5. These sequences may be fragments of the sequence of SEQ ID NO. 1, 3 or 5 or nucleic acid sequences that are related to such fragments in any of the ways described above. Nucleic acid sequences of the invention will preferably comprise at least 50 bases or base pairs, for example 50 to 100, 100 to 500, 500 to 1000 or 1000 to 2000 bases or base pairs.

20

25

30

Any combination of the above-mentioned degrees of homology and minimum sizes may be used to defined polynucleotides of the invention, with the more stringent

combinations (e.g. higher homology over longer lengths and/or hybridisation under more stringent conditions) being preferred. Thus, for example a polynucleotide which is at least 90% homologous over 100, preferably over 200 nucleotides forms one aspect of the invention, as does a polynucleotide which is at least 95%

5 homologous over 100 or 200 nucleotides.

Polynucleotides of the invention may comprise DNA or RNA. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to polynucleotides are known in the art.

10 Modifications may, for example enhance resistance to nucleases and/or enhance ability to enter cells. For example, phosphorothioate oligonucleotides may be used. Other deoxynucleotide analogs include methylphosphonates, phosphoramidates, phosphorodithioates, N3'P5'-phosphoramidates and oligoribonucleotide phosphorothioates and their 2'-O-alkyl analogs and 2'-O-methyliribonucleotide
15 methylphosphonates. A further possible modification is the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule.

Alternatively mixed backbone oligonucleotides (MBOs) may be used. MBOs contain segments of phosphothioate oligodeoxynucleotides and appropriately placed
20 segments of modified oligodeoxy- or oligoribonucleotides. MBOs have segments of phosphorothioate linkages and other segments of other modified oligonucleotides, such as methylphosphonate, which is non-ionic, and very resistant to nucleases or 2'-O-alkyloligoribonucleotides. For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any
25 method available in the art. Such modifications may be carried out in order to enhance the *in vivo* activity or lifespan of polynucleotides of the invention.

Polynucleotides of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe, e.g. labelled with a
30 revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other

fragments will preferably be at least 10, preferably at least 15 or 20, for example at least 25, 30 or 40 nucleotides in length. These will be useful in identifying species homologues and allelic variants as discussed above.

- 5 Polynucleotides such as a DNA polynucleotides and primers according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques. The polynucleotides are typically provided in isolated and/or purified form.
- 10 In general, primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.
- 15 Genomic clones corresponding to the cDNAs of SEQ ID NOs. 1, 3 and 5 containing, for example introns and promoter regions are also aspects of the invention and may also be produced using recombinant means, for example using PCR (polymerase chain reaction) cloning techniques.
- 20 The 4-5-6 exon pattern of MGF is characteristic of polynucleotides of the invention. Any suitable method may be used to ensure that this pattern is reflected in the coding sequence, and thus in the encoded polypeptide. For example, cDNA sequences lacking introns and splice signals and including the coding sequences of exons 4, 5 and 6 may be used. Alternatively, genomic DNA may be used if it will be correctly
- 25 spliced in the situation at hand.

Although in general the techniques mentioned herein are well known in the art, reference may be made in particular to Sambrook *et al* (1989), *Molecular Cloning: A Laboratory Manual*.

30 Polynucleotides which are not 100% homologous to the sequences of the present

invention but fall within the scope of the invention, as described above, can be obtained in a number of ways, for example by probing cDNA or genomic libraries from other plant species with probes derived from SEQ ID NO. 1, 3 or 5. Degenerate probes can be prepared by means known in the art to take into account the possibility of degenerate variation between the DNA sequences of SEQ ID NO. 1, 3 or 5 and the sequences being probed for under conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C), or other suitable conditions (e.g. as described above).

Allelic variants and species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding likely conserved amino acid sequences. Likely conserved sequences can be predicted from aligning the amino acid sequences of the invention (SEQ ID NO. 2, 4 or 6) with each other and/or with those of any homologous sequences known in the art. The primers will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.

Alternatively, such polynucleotides may be obtained by site-directed mutagenesis of sequences of SEQ ID NO. 1, 3 or 5 or allelic variants thereof. This may be useful where, for example silent codon changes are required to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequences may be desired in order to introduce restriction enzyme recognition sites, or to alter the properties or function of the polypeptides encoded by the polynucleotides.

The invention further provides double stranded polynucleotides comprising a polynucleotide of the invention and its complement.

Polynucleotides, probes or primers of the invention may carry a revealing label. Suitable labels include radiosotopes such as ^{32}P or ^{35}S , enzyme labels, or other

protein labels such as biotin. Such labels may be added to polynucleotides, probes or primers of the invention and may be detected using techniques known *per se*.

Production of polypeptides

5

Polypeptides of the invention may be produced in any suitable manner. In some embodiments they may be extracted from animal tissues. However, it is preferred that they be produced recombinantly from polynucleotides of the invention. This can be done using known techniques.

10

Repair of nerve damage

Localisation of MGF at the site of the nerve damage

15 MGF may be localised at the site of the nerve damage by any suitable means. For example, it can be localised at the damage site within a matrix, e.g. a gel or solid.

Preferably, MGF is localised at the damage site by means of a conduit around the nerve at the damage site. This is especially preferred where it is desired to bridge a gap in a severed nerve. However, other approaches may be better where the nerve is not severed, but rather damaged or degenerating. One example of such a condition is neuropraxia.

20

Conduits

25

A conduit may be placed around the nerve damage site. The presence of the conduit *per se* may encourage nerve damage repair but the localisation of MGF by the conduit will enhance this.

30

The conduit may be composed of any suitable material. For example, it may be composed of a non-bioabsorbable material such as silicone, which has been widely

used in the past.

However, bioabsorbable materials are preferred, as they can be absorbed by the body when the damage is repaired. Collagen conduits (available from Integra Life Sciences) are one option in this respect.

In general, flexibility and low inflammatory response are desirable characteristics of conduits of the invention.

Conduits comprising, or composed of, PHB elicit only low inflammatory (macrophage) response. They are also known to have positive effect on nerve regeneration independent of MGF (see above) so a combined treatment will be particularly effective.

PHB is a bacterial product and occurs in granular form in the bacterial cytoplasm. Preferably, PHB of bacterial origin will be used, though PHB from other sources can also be used in appropriate. PHB can be formed into bioabsorbable sheets and such sheets are preferably used to form the conduits of the invention.

Conduits, especially PHB conduits, may be formed and put in place by any known method. The methods of Hazari *et al*, 1999 (*Supra*) are preferred.

In particular, conduits are normally formed from PHB sheets cut so that the orientation of PHB fibres is along the length of the nerve. This promotes nerve damage repair by contact guidance.

A conduit is then formed by rolling the sheet around an object of suitable diameter, e.g. a 16 G intravenous cannula, thus standardising the internal diameter of the coagulate. A 16 G intravenous cannula gives an internal diameter of 1.6 mm.

However, other internal diameters can be achieved by rolling around different template objects. A person of skill in the art will be able to select the correct

size for the situation concerned. The rolled sheets are then sealed longitudely. Preferably, an adhesive is used, e.g. a cyano-acrylate glue (for example, histoacryl®, Braun Melsungen AG, Melsungen, Germany). Then, the conduit, preferably still rolled around the template object, is typically presoaked in saline to saturate the polymer and ensure maximum expansion of the fibres without a reduction in the internal diameter of the conduit. The skilled person will be able to determine a suitable size for the conduit based on the nerve damage to be repaired. However, a conduit will typically be formed from a rectangular sheet of PHB cut from a larger sheet. A person of skill in the art will be able to select the correct size for the situation concerned.

As discussed above, a conduit will be typically formed from a rolled sheet. However, conduits can also be manufactured as pre-formed tubes.

The conduits can be put in place by any means known in the art, for example by the surgical techniques discussed in Hazari *et al.* Typically, a conduit will be used to bridge the severed ends of the nerve by entubulating both ends of the nerve within the conduit and securing with sutures to the epineurium. The length of the conduit will be chosen according to the length of the gap. A person skilled in the art will be able to select the correct size for the situation concerned. Typically, a short segment of each nerve stump will be entubulated.

In a preferred embodiment, the conduits of the invention are used to repair nerve damage that involves severing of the nerve.

Preferably, the nerves to which damage is to be repaired are peripheral nerves, e.g. nerves in the arms or legs.

MGF according to the invention may be introduced into the conduit of the invention by any suitable means. For example, it may be coated on the inside of the conduit, impregnated into the conduit, e.g. during the saline soaking step mentioned above,

provided in a matrix, e.g. a gel matrix within the conduit or around the outside the conduit; alternatively, it may be delivered to the conduit *in situ*, e.g. by injection. The protein may be attached to the conduit by any suitable means.

5 *Preventing target organ degeneration*

When a nerve that innervates an organ (a "target" organ) is damaged, especially severed, the organ may degenerate because of the absence of innervation. Therefore, localisation of MGF around the nerve damage site is preferably performed in
10 combination with a treatment that prevents or diminishes target organ degeneration. Any suitable treatment known in the art may be used.

In particular, where the target organ is a muscle, MGF can be used to prevent apoptosis of the muscle cells and thus prevent or diminish degeneration. MGF or an
15 MGF-encoding nucleic acid can be delivered in any suitable way to achieve this. In particular, an MGF encoding nucleic acid can be introduced by intramuscular injection and expressed *in situ* to generate MGF. Other growth factors can also be used as appropriate.

20 Other neurotrophic factors, including glial cell-derived neurotrophic factor, brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin 4/5, may also be used, as they are found in skeletal muscle and other target organs, and they promote the survival of a variety of neurone types including motoneurons (e.g. Bock G.R. & Goode, 1996, Growth factors as drugs for neurological and sensory disorders. Ciba
25 Foundation Symposium 196. New York: John Wiley & Sons).

Pharmaceutical formulations for nerve damage repair

The polypeptides and nucleic acids of the invention are preferably delivered in the
30 form of a pharmaceutical formulation comprising a pharmaceutically acceptable carrier or diluent. Any suitable pharmaceutical formulation may be used.

For example, suitable formulations may include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, bactericidal antibiotics and solutes which render the formulation isotonic with the bodily fluids of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers. For example, sealed ampoules and vials, and may be stored in a frozen or freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.

10

In particular, formulations that encourage localisation of MGF at the site of nerve damage are preferred, for example gels and suspensions that discourage the active ingredient from moving away from the site.

15 Owing to MGF's short half-life, slow-release or delivery agents may be used. Any suitable pharmaceutical formulation may be used to effect slow-release of MGF of the invention. Liposome formulations are one possibility.

20 In particular, a slow release "toothpaste-type" matrix is preferred. This can be coated on to the inside of a conduit of the invention. A similar formulation, extruded from a syringe, could be used to combat degeneration of target organs, especially muscles whilst nerve damage is repaired.

25 It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question. Sterile, pyrogen-free aqueous and non-aqueous solutions are preferred.

Dosages for nerve damage repair

30

The proteins, nucleic acids and vectors of the invention may be delivered in any

suitable dosage, and using any suitable dosage regime. Persons of skill in the art will appreciate that the dosage amount and regime may be adapted to ensure optimal treatment of the particular condition to be treated, depending on numerous factors. Some such factors may be the age, sex and clinical condition of the subject to be treated and of course the type and severity of nerve damage concerned.

As a guideline, amounts of MGF in the region of from 1 to 1000 mg, from 10 to 100 mg and 100 to 500 mg or from 500 to 1000 mg may be localised around the site of the nerve damage.

Dosage schedules will also vary according to the condition to be treated. Typically, however, all of the MGF necessary will be administered at the outset of the procedure so that the surgical insertion can be closed. As discussed above, slow release formulations may be used to ensure delivery over a period of time at the nerve damage site. This is particularly desirable in view of MGF's short half-life.

Combinations of MGF and other neurotrophic factors in nerve damage repair

MGF polypeptides and nucleic acids of the invention can be administered in combination with other neurologically active agents. This may be either to enhance repair of nerve damage or to prevent or diminish target organ degeneration or both. Any additional neurological active agent may be used in this way. Such agents may be non-polypeptide molecules or they may be polypeptides. If they are polypeptides, they may be delivered as polypeptides or as nucleic acids encoding such polypeptides. This may be done by any suitable method known in the art.

Polypeptide growth factors having neurological activity are preferred. For example, neurotrophins such as Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), NT-4, NT-5 or Nerve Growth Factor (NGF) may be used. Similarly, neurologically active cytokines such as Ciliary Neurotrophic Factor (CNTF) can be used. Similarly, neurologically active transcription factors such as Brn 3a, Brn 3b

and Brn 3c may be used.

When an MGF of the invention is combined with another neurologically active agent in the treatment of a neurological disorder the two may be combined in the same pharmaceutical composition. Alternatively, they may be administered in separate compositions. They may be administered simultaneously, separately or sequentially and at the same site or a different site. For example, MGF may be present within a conduit of the invention that joins the two ends of a severed nerve, and another growth factor may be administered either within the conduit to assist MGF's nerve repair more action, and/or outside the conduit, or generally to the target organ to stop its degeneration whilst the nerve is repaired.

EXAMPLES

Introduction

5

In this study, we have used a model of axotomy-induced motoneuronal degeneration in adult rats to examine the protective effects of two isoforms of insulin-like growth factor-I (IGF-I): the commonly-used liver-type isoform (L.IGF-I) and a newly-identified splice variant of IGF-I which is produced by active muscle (Yang *et al*,
10 1996) and which we have termed "mechano growth factor" (MGF). Our analysis of the structure of MGF indicates that it probably has different tissue binding and a shorter half-life than L.IGF-I making it particularly suited to mediating such local interactions in a paracrine/autocrine manner. To enable the local action of L.IGF-I and MGF at the neuromuscular junction and avoid the need for repeated injections of
15 these short half-life molecules, we used a plasmid DNA vector to deliver the genes for these growth factors to muscles.

Methods

20 Three 20µl equidistant injections were made into the right whisker pad of lightly-anaesthetised (2% halothane) 6m Sprague-Dawley rats (n=4 per group). In the first group (plasmid), 1.5µg/µl plasmid DNA containing the rat MGF gene was injected and in the third group 0.65µg/µl plasmid DNA containing the rat MGF gene was injected. After 7 days, the right facial nerve was avulsed as it emerged from the
25 stylomastoid foramen using gentle traction. In other groups, the right facial nerve was crushed (n=4) or avulsed (n=4) without prior intramuscular injection of plasmid. After 1 month, all rats, including 4 non-operated rats, were anaesthetised then perfused with 4% paraformaldehyde and the region of the brainstem containing the facial nucleus sectioned serially at 70µm using a vibratome. Every 5th section was
30 taken in a systematic random manner and stained with the fluorescent dye YOYO (1:1000, molecular probes) for estimation of total facial motoneurone number using a

modification of the discetor method for use in the confocal microscope (Johnson *et al*, 1998). Briefly, 2 optical sections separated by 10µm were taken through the 70µm vibratome slice, one image was stored as shades of green and the other as shades of red. The two optical sections were then merged on screen and only those neurones which were present in one optical section but not the other (which in this case were green, but not red or shades of yellow) were counted. After determining the volume of the facial nucleus using stereology (West M.J. Trends in Neuroscience 1999. 22: 51-61) the total number of facial motoneurones was then calculated.

10 **Results**

The normal adult rat facial nucleus contains approximately 3,500 motoneurones (Table 1, Figure 1). 1 month following nerve crush, approximately 15% of the motoneurones are lost ipsilaterally ($p < 0.05$, Mann Whitney U test), while 1 month following nerve avulsion approximately 75% of the motoneurones are lost (Figure 2). Injection of plasmid DNA alone into the snout 7 days before avulsion had no effect on the massive motoneuronal loss seen 1 month later (Figure 3). However, prior intramuscular injection of the plasmid containing the gene for L.IGF-I reduced the motoneuronal loss 1 month following avulsion to 53% and injection of the plasmid containing the MGF gene reduced motoneuronal loss 1 month following avulsion to 21% (Figure 4).

TABLE 1

Total numbers of motoneurons in the facial motor nucleus 1 month following nerve avulsion (a simple tug to damage the nerve) with or without prior intramuscular gene transfer

	No avulsion		Crush		Avulsion	
	right	left	right	left	right	left
rat 1	3676	3404	3014	3619	884	3323
rat 2	3622	3118	2889	3404	889	3372
rat 3	3631	3385	2903	3314	719	3397
rat 4	3666	3233	3083	3523	733	3023
mean	3648.7	3285	2972.3	3465	806.3	3278.8
sd	22.8	116.9	80.2	115.8	80.4	150.0

	Control plasmid-avulsion		IGF-avulsion		MGF-avulsion	
	right	left	right	left	right	left
rat 1	750	3384	1699	3386	2674	3624
rat 2	798	3488	1556	3413	2934	3582
rat 3	819	3631	1660	3438	2800	3561
rat 4	869	3606	1640	3655	2823	3429
mean	809	3527.3	1638.8	3473	2807.8	3549
sd	42.7	98.8	52.3	106.7	92.4	72.9

REFERENCES

- Chew *et al*, *Endocrinology* 136, No. 5 (1995)
- Eisen *et al*, "*Amyotrophic Lateral Sclerosis*" (Cambridge University Press, Cambridge, 1998)
- Hazari *et al*, *British J. Plastic Surgery* 52, 653-57 (1999)
- Goldspink *et al*, *J. Physiol.* 496, 1628 (1996)
- Jansen *et al*, *Mol. Cell Endocrinology* 78: 115-25 (1991)
- Johnson *et al*, *Neuroscience* 84: 141-150 (1998)
- Layall, "*Transcriptional regulation of the ovine IGF-I gene*", PhD Thesis, University of Cambridge (1996)
- Lundborg *et al*, *J. Hand Surgery* 22: 99-106 (1997)
- Mañes *et al*, *Endocrinology* 138: 905-915 (1997)
- McKoy *et al*, *J. Physiol.* 516.2, 583-592 (1999)
- Rotwein *et al*, *J. Biol. Chem.* 261:4828-3 (1986)
- Skarli *et al*, *J. Physiol.* 509.8, 192.8 (1998)
- Tobin *et al*, *Mol. Endocrinology* 1914-20 (1990)
- Vejsada *et al*, *Eur. J. Neurosci.* 7: 108-115 (1995)
- Vesjada *et al*, *Neuroscience* 84: 129-139 (1998)
- Yang *et al*, *Journal of muscle cell research and cell motility* 4: 487-496 (1996)

SEQUENCE LISTING

<110> UNIVERSITY COLLEGE LONDON

<120> TREATMENT OF NEUROLOGICAL DISORDERS

<130> P77091 TAC AB

<140>

<141>

<160> 14

<170> PatentIn Ver. 2.1

<210> 1

<211> 518

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(330)

<400> 1

```

gga ccg gag acg ctc tgc ggg gct gag ctg gtg gat gct ctt cag ttc   48
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
      1              5              10              15
gtg tgt gga gac agg ggc ttt tat ttc aac aag ccc aca ggg tat ggc   96
Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
              20              25              30
tcc agc agt cgg agg gcg cct cag aca ggc atc gtg gat gag tgc tgc  144
Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
              35              40              45
ttc cgg agc tgt gat cta agg agg ctg gag atg tat tgc gca ccc ctc  192
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
      50              55              60

```

aag cct gcc aag tca gct cgc tct gtc cgt gcc cag cgc cac acc gac 240
 Lys Pro Ala Lys Ser Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
 65 70 75 80
 atg ccc aag acc cag aag tat cag ccc cca tct acc aac aag aac acg 288
 Met Pro Lys Thr Gln Lys Tyr Gln Pro Pro Ser Thr Asn Lys Asn Thr
 - 85 90 95
 aag tct cag aga agg aaa gga agt aca ttt gaa gaa cac aag 330
 Lys Ser Gln Arg Arg Lys Gly Ser Thr Phe Glu Glu His Lys
 100 105 110
 tagagggagt gcaggaaaca agaactacag gatgtagaa gacccttctg aggagtgaag 390
 aaggacaggc caccgcagga ccctttgctc tgcacagtta cctgtaaaca ttggaatacc450
 ggccaaaaaa taagtttgat cacatttcaa agatggcatt tcccccaatg aaatacacaa510
 gtaaacad 518

<210> 2

<211> 110

<212> PRT

<213> Homo sapiens

<400> 2

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
 1 5 10 15
 Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
 20 25 30
 Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
 35 40 45
 Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
 50 55 60
 Lys Pro Ala Lys Ser Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
 65 70 75 80

Met Pro Lys Thr Gln Lys Tyr Gln Pro Pro Ser Thr Asn Lys Asn Thr
 85 90 95
 Lys Ser Gln Arg Arg Lys Gly Ser Thr Phe Glu Glu His Lys
 100 105 110

<210> 3

<211> 539

<212> DNA

<213> Rat

<220>

<221> CDS

<222> (1)..(333)

<400> 3

gga cca gag acc ctt tgc ggg gct gag ctg gtg gac gct ctt cag ttc 48
 Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
 1 5 10 15
 gtg tgt gga cca agg ggc ttt tac ttc aac aag ccc aca gtc tat ggc 96
 Val Cys Gly Pro Arg Gly Phe Tyr Phe Asn Lys Pro Thr Val Tyr Gly
 20 25 30
 tcc agc att cgg agg gca cca cag acg ggc att gtg gat gag tgt tgc 144
 Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
 35 40 45
 ttc cgg agc tgt gat ctg agg agg ctg gag atg tac tgt gtc cgc tgc 192
 Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Val Arg Cys
 50 55 60
 aag cct aca aag tca gct cgt tcc atc cgg gcc cag cgc cac act gac 240
 Lys Pro Thr Lys Ser Ala Arg Ser Ile Arg Ala Gln Arg His Thr Asp
 65 70 75 80
 atg ccc aag act cag aag tcc cag ccc cta tcg aca cac aag aaa agg 288

Met Pro Lys Thr Gln Lys Ser Gln Pro Leu Ser Thr His Lys Lys Arg
85 90 95
aag ctg caa agg aga agg aaa gga agt aca ctt gaa gaa cac aag 333
Lys Leu Gln Arg Arg Arg Lys Gly Ser Thr Leu Glu Glu His Lys
100 105 110
tagaggaagt gcaggaaaca agacctacag aatgtaggag gagcctcccg aggaacagaa393
aatgccacgt caccgcaaga tcctttgctg cttgagcaac ctgcaaaaca tcggaacacc453
tgccaaatat caataatgag ttcaatatca tttcagagat gggcatttcc ctcaatgaaa513
tacacaagta aacattcccc gaattc 539

<210> 4

<211> 111

<212> PRT

<213> Rat

<400> 4

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
1 5 10 15
Val Cys Gly Pro Arg Gly Phe Tyr Phe Asn Lys Pro Thr Val Tyr Gly
20 25 30
Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
35 40 45
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Val Arg Cys
50 55 60
Lys Pro Thr Lys Ser Ala Arg Ser Ile Arg Ala Gln Arg His Thr Asp
65 70 75 80
Met Pro Lys Thr Gln Lys Ser Gln Pro Leu Ser Thr His Lys Lys Arg
85 90 95
Lys Leu Gln Arg Arg Arg Lys Gly Ser Thr Leu Glu Glu His Lys
100 105 110

<210> 5

<211> 523

<212> DNA

<213> RABBIT

<220>

<221> CDS

<222> (1)..(333)

<400> 5

gga ccg gag acg ctc tgc ggt gct gag ctg gtg gat gct ctt cag ttc	48
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe	
1 5 10 15	
gtg tgt gga gac agg ggc ttt tat ttc aac aag ccc aca gga tac ggc	96
Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly	
20 25 30	
tcc agc agt cgg agg gca cct cag aca ggc atc gtg gat gag tgc tgc	144
Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys	
35 40 45	
ttc cgg agc tgt gat ctg agg agg ctg gag atg tac tgt gca ccc ctc	192
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu	
50 55 60	
aag ccg gca aag gca gcc cgc tcc gtc cgt gcc cag cgc cac acc gac	240
Lys Pro Ala Lys Ala Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp	
65 70 75 80	
atg ccc aag act cag aag tat cag cct cca tct acc aac aag aaa atg	288
Met Pro Lys Thr Gln Lys Tyr Gln Pro Pro Ser Thr Asn Lys Lys Met	
85 90 95	
aag tct cag agg aga agg aaa gga agt aca ttt gaa gaa cac aag	333
Lys Ser Gln Arg Arg Arg Lys Gly Ser Thr Phe Glu Glu His Lys	
100 105 110	

523

<213> RABBIT

Gly	Pro	Glu	Thr	Leu	Cys	Gly	Ala	Glu	Leu	Val	Asp	Ala	Leu	Gln	Phe
1				5					10					15	
Val	Cys	Gly	Asp	Arg	Gly	Phe	Tyr	Phe	Asn	Lys	Pro	Thr	Gly	Tyr	Gly
			20					25					30		
Ser	Ser	Ser	Arg	Arg	Ala	Pro	Gln	Thr	Gly	Ile	Val	Asp	Glu	Cys	Cys
		35					40					45			
Phe	Arg	Ser	Cys	Asp	Leu	Arg	Arg	Leu	Glu	Met	Tyr	Cys	Ala	Pro	Leu
	50					55				60					
Lys	Pro	Ala	Lys	Ala	Ala	Arg	Ser	Val	Arg	Ala	Gln	Arg	His	Thr	Asp
65					70					75					80
Met	Pro	Lys	Thr	Gln	Lys	Tyr	Gln	Pro	Pro	Ser	Thr	Asn	Lys	Lys	Met
				85					90					95	
Lys	Ser	Gln	Arg	Arg	Arg	Lys	Gly	Ser	Thr	Phe	Glu	Glu	His	Lys	
		100						105					110		

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: translation
initiation sequence

<400> 7

gccaccatgg

10

<210> 8

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: translation
initiation sequence

<400> 8

gcccccatgg

10

<210> 9

<211> 316

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(315)

<400> 9

gga ccg gag acg ctc tgc ggg gct gag ctg gtg gat gct ctt cag ttc 48

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe

1 5 10 15

gtg tgt gga gac agg ggc ttt tat ttc aac aag ccc aca ggg tat ggc 96

Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly

20 25 30

tcc agc agt cgg agg gcg cct cag aca ggc atc gtg gat gag tgc tgc 144

Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys

35 40 45

ttc cgg agc tgt gat cta agg agg ctg gag atg tat tgc gca ccc ctc 192

Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu

50 55 60

aag cct gcc aag tca gct cgc tct gtc cgt gcc cag cgc cac acc gac 240

Lys Pro Ala Lys Ser Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp

65 70 75 80

atg ccc aag acc cag aag gaa gta cat ttg aag aac gca agt aga ggg 288

Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Ala Ser Arg Gly

85 90 95

agt gca gga aac aag aac tac agg atg ag 317

Ser Ala Gly Asn Lys Asn Tyr Arg Met

100 105

<210> 10

<211> 105

<212> PRT

<213> Homo sapiens

<400> 10

Gly	Pro	Glu	Thr	Leu	Cys	Gly	Ala	Glu	Leu	Val	Asp	Ala	Leu	Gln	Phe
1				5				10					15		
Val	Cys	Gly	Asp	Arg	Gly	Phe	Tyr	Phe	Asn	Lys	Pro	Thr	Gly	Tyr	Gly
			20					25					30		
Ser	Ser	Ser	Arg	Arg	Ala	Pro	Gln	Thr	Gly	Ile	Val	Asp	Glu	Cys	Cys
			35				40					45			
Phe	Arg	Ser	Cys	Asp	Leu	Arg	Arg	Leu	Glu	Met	Tyr	Cys	Ala	Pro	Leu
			50				55				60				
Lys	Pro	Ala	Lys	Ser	Ala	Arg	Ser	Val	Arg	Ala	Gln	Arg	His	Thr	Asp
			65				70				75			80	
Met	Pro	Lys	Thr	Gln	Lys	Glu	Val	His	Leu	Lys	Asn	Ala	Ser	Arg	Gly
				85					90					95	
Ser	Ala	Gly	Asn	Lys	Asn	Tyr	Arg	Met							
			100					105							

<210> 11

<211> 487

<212> DNA

<213> Rat

<220>

<221> CDS

<222> (1)..(315)

<400> 11

gga	cca	gag	acc	ctt	tgc	ggg	gct	gag	ctg	gtg	gac	gct	ctt	cag	ttc	48
Gly	Pro	Glu	Thr	Leu	Cys	Gly	Ala	Glu	Leu	Val	Asp	Ala	Leu	Gln	Phe	
1				5				10					15			
gtg	tgt	gga	cca	agg	ggc	ttt	tac	ttc	aac	aag	ccc	aca	gtc	tat	ggc	96

Val Cys Gly Pro Arg Gly Phe Tyr Phe Asn Lys Pro Thr Val Tyr Gly
 20 25 30

tcc agc att cgg agg gca cca cag acg ggc att gtg gat gag tgt tgc 144
 Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
 35 40 45

ttc cgg agc tgt gat ctg agg agg ctg gag atg tac tgt gtc cgc tgc 192
 Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Val Arg Cys
 50 55 60

aag cct aca aag tca gct cgt tcc atc cgg gcc cag cgc cac act gac 240
 Lys Pro Thr Lys Ser Ala Arg Ser Ile Arg Ala Gln Arg His Thr Asp
 65 70 75 80

atg ccc aag act cag aag gaa gta cac ttg aag aac aca agt aga gga 288
 Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Thr Ser Arg Gly
 85 90 95

agt gca gga aac aag acc tac aga atg taggaggagc ctcccaggaga 335
 Ser Ala Gly Asn Lys Thr Tyr Arg Met
 100 105

acagaaaatg ccacgtcacc gcaagatcct ttgctgcttg agcaacctgc aaaacatcgg395
 aacacctgcc aaatatcaat aatgagttca atatcatttc agagatgggc atttccctca455
 atgaaataca caagtaaaca ttcccgggaat tc 487

<210> 12

<211> 105

<212> PRT

<213> Rat

<400> 12

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
 1 5 10 15

Val Cys Gly Pro Arg Gly Phe Tyr Phe Asn Lys Pro Thr Val Tyr Gly
20 25 30

Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
35 40 45

Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Val Arg Cys
50 55 60

Lys Pro Thr Lys Ser Ala Arg Ser Ile Arg Ala Gln Arg His Thr Asp
65 70 75 80

Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Thr Ser Arg Gly
85 90 95

Ser Ala Gly Asn Lys Thr Tyr Arg Met
100 105

<210> 13

<211> 471

<212> DNA

<213> Rabbit

<220>

<221> CDS

<222> (1)..(315)

<400> 13

gga ccg gag acg ctc tgc ggt gct gag ctg gtg gat gct ctt cag ttc 48
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
1 5 10 15
gtg tgt gga gac agg ggc ttt tat ttc aac aag ccc aca gga tac ggc 96

Val	Cys	Gly	Asp	Arg	Gly	Phe	Tyr	Phe	Asn	Lys	Pro	Thr	Gly	Tyr	Gly	
tcc	agc	agt	cgg	agg	gca	cct	cag	aca	ggc	atc	gtg	gat	gag	tgc	tgc	144
Ser	Ser	Ser	Arg	Arg	Ala	Pro	Gln	Thr	Gly	Ile	Val	Asp	Glu	Cys	Cys	
ttc	cgg	agc	tgt	gat	ctg	agg	agg	ctg	gag	atg	tac	tgt	gca	ccc	ctc	192
Phe	Arg	Ser	Cys	Asp	Leu	Arg	Arg	Leu	Glu	Met	Tyr	Cys	Ala	Pro	Leu	
aag	ccg	gca	aag	gca	gcc	cgc	tcc	gtc	cgt	gcc	cag	cgc	cac	acc	gac	240
Lys	Pro	Ala	Lys	Ala	Ala	Arg	Ser	Val	Arg	Ala	Gln	Arg	His	Thr	Asp	
atg	ccc	aag	act	cag	aag	gaa	gta	cat	ttg	aag	aac	aca	agt	aga	ggg	288
Met	Pro	Lys	Thr	Gln	Lys	Glu	Val	His	Leu	Lys	Asn	Thr	Ser	Arg	Gly	
agt	gca	gga	aac	aag	aac	tac	agg	atg	taggaagacc	cttctgagga						335
Ser	Ala	Gly	Asn	Lys	Asn	Tyr	Arg	Met								
gtgaagaagg	acaggccacc	gcaggaccct	ttgctctgca	cagttacctg	taaacattgg	395										
aataccggcc	aaaaaataag	tttgatcaca	tttcaaagat	ggcatttccc	ccaatgaaat	455										
acacaagtaa	acattc															471

<210> 14

<211> 105

<212> PRT

<213> Rabbit

<400> 14

Gly	Pro	Glu	Thr	Leu	Cys	Gly	Ala	Glu	Leu	Val	Asp	Ala	Leu	Gln	Phe
1				5					10					15	

Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
20 25 30
Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
35 40 45
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
50 55 60
Lys Pro Ala Lys Ala Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
65 70 75 80
Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Thr Ser Arg Gly
85 90 95
Ser Ala Gly Asn Lys Asn Tyr Arg Met
100 105

CLAIMS

1. Use of an MGF (mechano-growth factor) Insulin-like Growth Factor I (IGF-I) isoform comprising amino acid sequences encoded by nucleic acid sequences of IGF-I exons 4, 5 and 6 in the reading frame of MGF and having the ability to reduce motoneurone loss by 20% or greater in response to nerve avulsion, in the manufacture of a medicament for the treatment of nerve damage by localisation of MGF at the site of the damage.
2. Use according to claim 1 wherein the nerve damage is to a nerve of the peripheral nervous system (PNS).
3. Use according to claim 1 or 2 wherein MGF is localised at the site of the damage by means of a conduit placed around the nerve at the site of the damage.
4. Use according to claim 3 wherein the conduit comprises Poly-3-hydroxy-butyrate (PHB).
5. Use according to any one of the preceding claims wherein the damage comprises the severing of the nerve.
6. Use according to any one the preceding claims wherein treatment of nerve damage is combined with a treatment that prevents or diminishes degeneration of the target organ which the damaged nerve innervates.
7. Use according to claim 6 wherein the target organ is a muscle and treatment of the muscle with MGF or a polynucleotide encoding MGF prevents or diminishes degeneration.
8. Use according to claim 6 wherein treatment of the target organ with a polypeptide growth factor than than MGF prevents or diminishes degeneration.

9. Use according to any one of the preceding claims wherein the MGF has the ability to reduce motoneurone loss by 50% or greater or 80% or greater in response to nerve avulsion.
10. Use according to any one of the preceding claims wherein the MGF is unglycosylated.
11. Use according to any one of the preceding claims wherein the MGF has:
 - (a) the sequence of Human MGF (SEQ ID NO. 2, Rat MGF (SEQ ID NO. 4) or Rabbit MGF (SEQ ID NO. 6);
 - (b) a sequence having 70% or greater homology to a sequence of (a);
 - (c) a sequence comprising the amino acids encoded wholly or partly by exons 4, 5 and 6 of human, rat or rabbit MGF DNA of SEQ ID NO. 1, 3 or 5, or a sequence having 70% or greater homology thereto; or
 - (d) a sequence encoded by a nucleic acid sequence capable of selectively hybridising to a sequence of (a), (b) or (c).
12. Use according to any one of the preceding claims wherein the medicament further comprises another neurologically active agent or wherein treatment with MGF is carried out in combination with another neurologically active agent.
13. A product comprising:
 - (a) an MGF IGF-I isoform as defined in any one of claims 1, 9, 10 or 11; and
 - (b) a conduit as defined in claim 3 or 4; and optionally
 - (c) a polypeptide growth factor which prevents or diminishes degeneration; and optionally
 - (d) another neurologically active agent

for simultaneous, separate or sequential use in the treatment of nerve damage.

14. A kit for the treatment of nerve damage comprising:

- (a) an MGF IGF-I isoform as defined in any one of claims 1, 9, 10 or 11; and
- (b) a conduit as defined in claim 3 or 4; and optionally
- (c) a polypeptide growth factor which prevents or diminishes degeneration; and optionally
- (d) another neurologically active agent.

15. A method of treating nerve damage comprising administering to a subject in need thereof an effective non-toxic amount of an MGF IGF-I isoform as defined in any one of claims 1, 9, 10 or 11 by localising said MGF at the site of said damage.


16. Use according to claim 12, a product or kit according to claim 13 or 14, or a method according to claim 15 wherein the other neurologically active agent is a polypeptide growth factor or a nucleic acid encoding a polypeptide growth factor.

ABSTRACT

REPAIR OF NERVE DAMAGE

The invention provides use of an MGF (mechano-growth factor) Insulin-like Growth Factor I (IGF-I) isoform comprising amino acid sequences encoded by nucleic acid sequences of IGF-I exons 4, 5 and 6 in the reading frame of MGF and having the ability to reduce motoneurone loss by 20% or greater in response to nerve avulsion in the manufacture of a medicament for the treatment of nerve damage by localisation of MGF at the site of the damage.

FIGURE 1






FIGURE 2

Avulsion






FIGURE 3

Plasmid





FIGURE 4

MGF Plasmid





cDNA sequences of Human MGF

Exon 3
GGACCGGAGACGGCTCTGCGGGGCTGAGCTGGTGGATGCCCTCCTCAGTTCGTGTGTGGAGACAGGGGCTTTTATTTCACAACAGCCACAGGGTATGGCTTCAGCAGTCGG

Exon 4
AGGGCGCCTCAGACAGGCATCGTGGATGAGTGTCTCCGGAGCTGTGATCTAAGGAGGCTGGAGATGTATTGCGCACCCCTCAAGCCCTGCCAAGTCAGCTCGCTC

Exon 5
TGTCCTGTGCCCCAGCGGCCACACCCGACATGCCCAAGACCCAGAGATATCAGCCCCCATCTACCAACAGANCAUGAAGTCTCAGAGAGGAAAGGAAGTACATTTTGAAG

Exon 6
AACACAAGTAGAGGGAGTGCAGGAAACAAGAACTACAGGATGTAGAAGACCCCTCTCTGGGAGTGAAGAAGGACAGGCCACCGCAGGCCCTTTTGCTCTTGCACAGTTTA

CTGTAAACAATTTGGATACCGGGGCCAAAAATAAGTTTGTATCATAATTTCAAGATGGCATTTCCCCCAATGAAATACACAAGTAAACAT

Protein sequence of Human MGF

Exon 3
GlyProGluThrLeuCysGlyAlaGluLeuValAspAlaLeuGlnPheValCysGlyAspArgGlyPheTyrPheAsnLysProThrGlyTyrGlySerSerSerAla

Exon 4

GargAlaProGlnThrGlyIleValAspGluCysCysPheArgSerCysAspLeuArgArgLeuGluMetTyrCysAlaProLeuLysProAlaLysSerAlaArgS

Exon 5
ErvAlaArgAlaGlnArgHisThrAspMetProLysThrGlnLysTyrGlnProProSerThrAsnLysAsnThrLysSerGlnArgArgLysGlySerThrPheGlu

Exon 6

GluHisLys

FIGURE 5

cdna sequences of Rat MGF

Exon 3
 GGACGAGAGACCCCTTTGGCGGGCTGAGCTGGTGGACCGCTCTTCAGTTCTGTTCTGGATCAAGGGGCTTTTACCTTCAACAAGCCACAGTCTATGGCTCCAGCATTCG
 Exon 4
 GAGGCAACACAGACGGGCCATTGTGGATGAGTGTGGCTCCGGAGCTGTGATCTGAGGAGGCTGGAGATGTACCTGTGTCCGCTGCAAGCCCTACAAAGTCAGCTCGTT
 Exon 5
 CCATCCGGCCCCAGCGCCACACTGACATGCCCAAGACTCAGANGTCCGAGCCCTATCTGACACACAAAGAAAGGAAGCTGCCAAGGAGAAAGGAAGGTACACTT
 Exon 6
 GAAGAACACAAGTAGAGGAAGTGCAGGAACAACAGACCTACAGATGTAGGAGGAGGCTCCCGAGGAACAGAAATGCCACGTCACCGGCACGATCCTTTGCTGCTTGA
 GCAACCTGCAGAAACATCGGACACACCTGCCAAATATCAATTAATGAGTTCAATATCATTTTCAGAGATGGGCAATTCCTTCAATGAAATACACAAGTAACATTCCTCCGGGA

ATTC

Protein sequence of Rat MGF

Exon 3
 GlyProGluThrLeuCysGlyAlaGluLeuValAspAlaLeuGluPheValCysGlyPheArgGlyPheTyrPheAsnLysProThrValTyrGlySerSerIleAla
 Exon 4
 GArgAlaProGluThrGlyIleValAspGluCysCysPheArgSerCysAspLeuArgArgLeuGluMetTyrCysValArgCysLysProThrLysSerAlaArgS
 Exon 5
 ErIleArgAlaGlnArgHisThrAspMetProLysThrGlnLysSerGlnProLeuSerThrHisLysArgGlyLeuGluArgArgGlySerThrIleu
 Exon 6
 GluGluIleLys

FIGURE 6

cdna sequences of Rabbit MGF

Exon 3
GGACCGGAGAGCGCTCTGCGGTGCTGAGCTGGTGGATGCTCTTCAGTTCGTGTGTGGAGACAGGAGCTTTTATTTCAACACAGCCCCACAGGATACGGCTCCACGACAGTGGGAGGGCACC

Exon 4

TCAGACAGGCATCGTGGATGAGTGTGCTTCCGGAGCTGTGATCTGAGGAGGCTGGAGATGTACTGTGCACCCCTCAAGCCCGGCAAGGCAGCCCGCTCCGTTCCGTGGCCACAGGACC

Exon 5

ACACCGACATGCCCAAGACTCAGAAGTATCAGGCTCCATCTACCAACCAAGAAAATGAAGTCTCAGAGGAGAGGAAGGAAGTACATTTGAAGAACACAAAGTAGAGGGAGTGCAGG

Exon 6

AAACAAGAACTACAGGATGTAGGAAGACCCCTTCTGAGGAGTGAAGAAGGACAGGCCACCGCAGGACCCCTTTGCTCTGCACAGTTACCTGTAAACATTTGGAAATACCGGCCCAAAAAAT

AAGTTTGATCACATTTCAAAGATGGCAATTTCCCCCAATGAATAACACAAAGTAAACATTTC

Protein sequence of Rabbit MGF

Exon 3
GlyProGluThrLeuCysGlyAlaGluLeuValAspAlaLeuGluPheValCysGlyAspArgGlyPheTyrPheAsnLysProThrGlyTyrGlySerSerSerArgArgAlaPrt

Exon 4

OGlnThrGlyIleValAspGluCysCysPheArgSerCysAspLeuArgArgLeuGluMetTyrCysAlaProLeuLysProAlaLysAlaAlaArgSerValArgAlaGluArgH

Exon 5

istThrAspMetProLysThrGlnLysTyrGlnProProSerThrAsnLysLysMetLysSerGlnArgArgArgLysGlySerThrPheGluGluHisLys

Exon 6

FIGURE 7

cdna sequence of human IGF-1

Exon 3
GGACCGGAGAGCGCTCTGCGGGGCTGAGCTGGTGGATGCTCTTTCAGTTCGCTGTGGAGACAGGGGCTTTTATTTCAACAAGCCCAAGGGTATGGCTCCAGCAGTCCGAGGGGCGGCC

Exon 4
TCAGACAGGCATCGTGGATGAGTGTCTTCCGGAGCTGTGATCTAAGGAGGCTGGAGATGTATTTGGCCACCCCTCAAGCCTGCCAAGTCAGCTCGCTCTGTCCGTGCCACAGCGGC

Exon 6
ACACCGACATGCCCCAAGACCCAGAGGAAGTACATTTGAAGAACGCCAAGTAGAGGGAGTGCAGGAACACAGAACATACAGGATGTAG

Protein sequence of human IGF-1

Exon 3
GlyProGluThrLeuCysGlyAlaGluLeuValAspAlaLeuGlnPheValCysGlyAspArgGlyPheTyrPheAsnLysProThrGlyTyrGlySerSerArgArgAlaPr

Exon 4
OGlnThrGlyIleValAspGluCysCysPheArgSerCysAspLeuArgArgLeuGluMetTyrCysAlaProLeuLysProAlaLysSerAlaArgSerValArgAlaGlnArgH

Exon 6
isThrAspMetProLysThrGlnLysGluValHisLeuLysAsnAlaSerArgGlySerAlaGlyAsnLysAsnTyrArgMet

FIGURE 8

cDNA sequences of rat IGF-1

Exon 3
 GGACCAGAGACCCCTTTGCGGGGCTGAGCTGGTGGAGGCTCTTCAGATTCTGTGTGGACCAAGGGGCTTTTACTTCAACAAGCCCAACAGTCTATGGCTCCAGCATTCGGAGGGCAAC
 Exon 4
 ACAGACGGGGCAATTGTGGATGAGTGTGCTTCCGGAGCTGTGATCTGAGGAGGCTGGAGATGTAAGTGTGTCCGCTGCAAGCCTACAAAGTCAGCTCGTTCCATCCGGGCCCCAGGGCC
 Exon 5
 ACACCTGACATGCCCAAGACTCAGAAGGAAGTACACTTGAAGAACACAAAGTAGAGGAAGTGCAGGAACAAAGACCTACAGAAATGTAGGAGGAGCCCTCCCCGGGAACAGAAAAATGCCA
 Exon 6
 CGTCACCGCAAGATCCCTTTGCTGCTTGAGCAACCTGCAAAACATCGGAACACCTGCCAAATATCAATATGAGTTCAATATCATTTTCAGAGATGGGCATTTCCCTCAATGAATATAC
 ACAAGTAAACATTTCCCGGAATTC

Protein sequences of rat IGF-1

Exon 3
 GlyProGluThrLeuCysGlyAlaGluLeuValAspAlaLeuGlnPheValCysGlyProArgGlyPheTyrPheAsnLysProThrValTyrGlySerSerIleArgArgAlaPhe
 Exon 4
 oGlnThrGlyIleValAspGluCysCysPheArgSerCysAspLeuArgArgLeuGluMetTyrCysValArgCysLysProThrLysSerAlaArgSerIleArgAlaGlnArgIle
 Exon 5
 isthrAspMetProLysThrGlnLysGluValHisLeuLysAsnThrSerArgGlySerAlaGlyAsnLysThrTyrArgMet
 Exon 6

FIGURE 9

cdna sequence of rabbit IGF-1

Exon 1
 GGACGGAGACGCTCTGGGGTGCTGAGCTGGTGGATGCTCTTCACATTCGTGTGTGGAGATAGGGGCTTTTATTTCAACAAGCCCCACAGGATACGGCTCCAGCAGTGGGAGGCACC
 Exon 4
 TCAGACAGGCATCGTGGATGAGTGTGCTTCCGGAGCTGTGATCTGAGGAGGCTGGAGATGTACTGTGCACCCCTCAAGCGGGCAAGGCAAGCCGGCTCCGTCCCTGCCCCAGGGCC
 Exon 6
 ACACCGACATGCCCAAGACTCAGAAGGAAGTACATTTGAAGAACACACAAAGTAGAGGGAGTGCAGGAAACAGAAGTACAGGATGTAGGAAGACCCCTTCTGAGGAGTGAAGAAGGACA
 GGCCACCGCAGGACCCCTTGCTCTGCACAGTTACCTGTAACATTTGGAATACCGGCCAAAAAATTAAGTTTGATCACAATTTCAAGAATGGCATTTCCCCCAATGTAATACACAAGTA
 AACATTTC

Protein sequence of rabbit IGF-1

Exon 3
 GlyProGluThrLeuCysGlyAlaGlnLeuValAspAlaLeuGlnPheValCysGlyAspArgGlyPheTyrPheAsnLysProThrGlyTyrGlySerSerArgArgAlaPro
 Exon 4
 OGlnThrGlyIleValAspGluCysCysPheArgSerCysAspLeuArgArgLeuGluMetTyrCysAlaProLeuLysProAlaLysAlaAlaArgSerValArgAlaGlnArgH
 isThrAspMetProLysThrGlnLysGluValHisLeuLysAsnThrSerArgGlySerAlaGlyAsnLysAsnTyrArgMet
 Exon 6

FIGURE 10

FIGURE 11

Exon 4																										
Hu MGF -	A	sn	Lys	Pro	Thr	Gly	Tyr	Gly	Ser	Ser	Ser	Arg	Arg	Ala	Pro	Gln	Thr	Gly	Ile	Val	Asp	Glu	Cys	Cys	Phe	
Rat MGF -	A	sn	Lys	Pro	Thr	Val	Tyr	Gly	Ser	Ser	Ser	Ile	Arg	Arg	Ala	Pro	Gln	Thr	Gly	Ile	Val	Asp	Glu	Cys	Phe	
Rab MGF -	A	sn	Lys	Pro	Thr	Gly	Tyr	Gly	Ser	Ser	Ser	Arg	Arg	Ala	Pro	Gln	Thr	Gly	Ile	Val	Asp	Glu	Cys	Cys	Phe	
Hu IGF -	A	sn	Lys	Pro	Thr	Gly	Tyr	Gly	Ser	Ser	Ser	Arg	Arg	Ala	Pro	Gln	Thr	Gly	Ile	Val	Asp	Glu	Cys	Cys	Phe	
Rat IGF -	A	sn	Lys	Pro	Thr	Val	Tyr	Gly	Ser	Ser	Ser	Ile	Arg	Arg	Ala	Pro	Gln	Thr	Gly	Ile	Val	Asp	Glu	Cys	Phe	
Rab IGF -	A	sn	Lys	Pro	Thr	Gly	Tyr	Gly	Ser	Ser	Ser	Arg	Arg	Ala	Pro	Gln	Thr	Gly	Ile	Val	Asp	Glu	Cys	Cys	Phe	
Hu MGF -	Arg	Ser	Cys	Asp	Leu	Arg	Arg	Arg	Leu	Glu	Met	Tyr	Cys	Ala	Pro	Leu	Lys	Pro	Ala	Lys	Ser	Ala	Arg	Ser	Val	
Rat MGF -	Arg	Ser	Cys	Asp	Leu	Arg	Arg	Arg	Leu	Glu	Met	Tyr	Cys	Val	Arg	Cys	Lys	Pro	Thr	Lys	Ser	Ala	Arg	Ser	Ile	
Rab MGF -	Arg	Ser	Cys	Asp	Leu	Arg	Arg	Arg	Leu	Glu	Met	Tyr	Cys	Ala	Pro	Leu	Lys	Pro	Ala	Lys	Ala	Arg	Ser	Val		
Hu IGF -	Arg	Ser	Cys	Asp	Leu	Arg	Arg	Arg	Leu	Glu	Met	Tyr	Cys	Ala	Pro	Leu	Lys	Pro	Ala	Lys	Ser	Ala	Arg	Ser	Val	
Rat IGF -	Arg	Ser	Cys	Asp	Leu	Arg	Arg	Arg	Leu	Glu	Met	Tyr	Cys	Val	Arg	Cys	Lys	Pro	Thr	Lys	Ser	Ala	Arg	Ser	Ile	
Rab IGF -	Arg	Ser	Cys	Asp	Leu	Arg	Arg	Arg	Leu	Glu	Met	Tyr	Cys	Ala	Pro	Leu	Lys	Pro	Ala	Lys	Ala	Arg	Ser	Ser	Val	
Exon 5																										
Hu MGF -	Arg	Ala	Gln	Arg	His	Thr	Asp	Met	pro	Lys	Thr	Gln	Lys		Tyr	Gln	Pro	Pro	Ser	Thr	Asn	Lys	Asn	Thr	Lys	
Rat MGF -	Arg	Ala	Gln	Arg	His	Thr	Asp	Met	pro	Lys	Thr	Gln	Lys		Ser	Gln	Pro	Leu	Ser	Thr	His	Lys	Lys	Arg	Lys	
Rab MGF -	Arg	Ala	Gln	Arg	His	Thr	Asp	Met	pro	Lys	Thr	Gln	Lys		Tyr	Gln	Pro	Pro	Ser	Thr	Asn	Lys	Lys	Met	Lys	
Hu IGF -	Arg	Ala	Gln	Arg	His	Thr	Asp	Met	pro	Lys	Thr	Gln	Lys													
Rat IGF -	Arg	Ala	Gln	Arg	His	Thr	Asp	Met	pro	Lys	Thr	Gln	Lys													
Rab IGF -	Arg	Ala	Gln	Arg	His	Thr	Asp	Met	pro	Lys	Thr	Gln	Lys													
Exon 6																										
Hu MGF -	Ser	Gln	Arg	Arg	Lys	G	ly	Ser	Thr	Phe	Glu	Glu	His	Lys												
Rat MGF -	Leu	Gln	Arg	Arg	Arg	L	ys	Gly	Ser	Thr	Leu	Glu	Glu	His	Lys											
Rab MGF -	Ser	Gln	Arg	Arg	Arg	L	ys	Gly	Ser	Thr	Phe	Glu	Glu	His	Lys											
Hu IGF -								Glu	Val	His	Leu	Lys	Asn	Ala	Ser	Arg	Gly	Ser	Ala	Gly	Asn	Lys	Asn	Tyr	Arg	Met
Rat IGF -								Glu	Val	His	Leu	Lys	Asn	Thr	Ser	Arg	Gly	Ser	Ala	Gly	Asn	Lys	Thr	Tyr	Arg	Met
Rab IGF -								Glu	Val	His	Leu	Lys	Asn	Thr	Ser	Arg	Gly	Ser	Ala	Gly	Asn	Lys	Asn	Tyr	Arg	Met

THIS PAGE BLANK (USPTO)